Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

Role of Surgery in Locally Advanced NSCLC

Memorial Sloan Kettering Cancer Center

K. Gray

ESMO 2024 Summary: Key Trial Insights on Managing NSCLC With Low PD-…

ecancer

L. Paz-Ares

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Adjuvant & Neoadjuvant Therapy in Early NSCLC With Actionable Genomi…

Fox Chase Cancer Center

J. Reuss

IO Advances in Metastatic NSCLC Treatment

Fox Chase Cancer Center

H. Borghaei

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

FDA Approval of Zenocutuzumab for Advanced NRG1 Fusion-Positive NSCL…

Memorial Sloan Kettering Cancer Center

A. Schram

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

Unresectable Stage 3 NSCLC: Patient Selection and Treatment Options

Fox Chase Cancer Center

C. Aggarwal

Neoadjuvant vs. Adjuvant: A New Paradigm for NSCLC

Total Health

D. Carbone

WCLC 2024 Review: MARIPOSA Trial - Extended Follow Up and Patient Re…

ecancer

E. Felip

Year in Review 2024 - Targeted Therapy for NSCLC

Nebraska Oncology Society

J. Murray

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel